Daraxonrasib: Survival time almost doubled in the study

Pancreatic cancer, medically known as pancreatic carcinoma, is a malignant tumour of the pancreas. In metastatic disease, the cancer has spread beyond the organ.

Daraxonrasib was investigated for an advanced form of the disease. The trial involved 500 previously treated patients with metastatic ductal pancreatic carcinoma. All patients had already received at least one course of treatment.

Early symptoms of pancreatic cancer can be non-specific. Possible initial signs include pain in the upper abdomen or back, although these may also have other causes. Individual symptoms are therefore not sufficient to diagnose the condition.

Persistent or worsening symptoms should be investigated by a doctor. If cancer is suspected, a CT scan and an MRI scan can show where the cancer is located and how far it has spread.

Treatment depends primarily on whether the tumour can be completely removed. If it is initially unclear whether the tumour is operable, chemotherapy prior to surgery may be used to shrink the tumour.

In the trial, Daraxonrasib was compared with chemotherapy.

Patients should not alter or stop their current treatment on their own. This also applies if initial results give cause for hope regarding further treatment.

Daraxonrasib targets the RAS signalling pathway. The active substance binds to cyclophilin A and forms an inhibitory complex with this protein.

The study’s conclusions have clear limitations:

• RAS G12 mutation: This was present in 91.8 per cent of study participants.
• Earlier stages of treatment: Whether the active ingredient could be used at these stages is still being investigated.
• Other types of cancer: The study does not suggest any benefit for these.

For the small group without the RAS G12 mutation, a systematic review advises caution in interpreting the results. The findings therefore do not show that Daraxonrasib is effective in all patients or for other types of cancer.

The study shows longer median values for overall survival and progression-free survival with Daraxonrasib. The comparison involved previously treated patients with metastatic ductal pancreatic carcinoma.

This meant that the median overall survival in the daraxonrasib group was almost doubled. The difference between 13.2 months and 6.7 months reflects the two study groups, not the potential course of the disease in an individual patient.

The median time to progression was also doubled with daraxonrasib. A median divides a group into two halves: half of the patients were above this value, the other half below it. This does not provide an individual prognosis.

Adverse effects occurred in both groups. Medically significant adverse effects of grade 3 or higher were slightly less common with daraxonrasib than with chemotherapy. These data do not specify the individual symptoms involved.

The authors of the systematic review cite the limited follow-up period and the small subgroups without the RAS G12 mutation as limitations. The results are therefore not generalisable to all patients with pancreatic cancer or to other types of cancer. No promise of a cure can be inferred from these findings.

Approval status currently differs between the USA and the European Union. According to a systematic review published in 2026, the FDA granted approval for Daraxonrasib on 26 August 2026 for certain adults with metastatic pancreatic adenocarcinoma.

For the EU, the EMA recommends the active substance for adults with metastatic pancreatic adenocarcinoma who have received at least one prior course of systemic therapy. The European Commission has yet to decide on its authorisation.

Daraxonrasib is therefore not yet officially authorised in Germany. The FDA’s decision does not automatically apply to Germany or other EU Member States.

Imaging tests determine the location of a suspected tumour and how far it has spread. If pancreatic cancer is suspected, computed tomography (CT) and magnetic resonance imaging (MRI) may be used for this purpose. The results help in deciding on further treatment.

If the tumour is operable, pancreatic surgery involves various procedures on the pancreas. The type of operation considered for pancreatic cancer depends on the location and extent of the tumour.

Daraxonrasib is used in a different treatment context. The medicine was investigated following prior treatment for metastatic disease. It does not replace diagnostic tests or the assessment of whether surgery is possible.